Infliximab and/or azathioprine in patients with Crohn's disease. Commented report on the SONIC trial.

Abstract

The SONIC trial assessed the efficacy of infliximab, azathioprine or combined therapy with infliximab and azathioprine in patients with moderate to severe Crohn's disease who had not been treated previously with any biological agents or immunosuppressants. The authors comment on the results of the SONIC trial and discuss how to apply them to clinical practice.

Keywords

• infliximab
• azathioprine
• combined therapy
• Crohn's disease